BioSpace News Archive

Drug Development

Eisai Reports Positive Phase III Trial Results of Investigational Anticancer Agent Lenvatinib in Unresectable Hepatocellular Carcinoma Published in The Lancet

The REFLECT study reported on in the paper was a multicenter, open-label, randomized, global Phase 3 study comparing the efficacy and safety of lenvatinib versus sorafenib.

February 15, 2018

·

16 min read

Business

Semler to Report Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on February 28, 2018

Doug Murphy-Chutorian, M.D., chief executive officer of Semler Scientific, will host a conference call at 11 a.m. ET the same day.

February 15, 2018

·

2 min read

Business

Ironwood Pharmaceuticals Provides Fourth Quarter and Full Year 2017 Investor Update

Ironwood ended 2017 with approximately $221 million of cash, cash equivalents and available-for-sale securities.

February 15, 2018

·

41 min read

Genetown

Glytec Release: Study Shows Computer-Guided Insulin Dosing Plus More Frequent Blood Glucose Testing Leads to Better Outcomes for Patients with Diabetes

The authors concluded that Glytec’s Glucommander Outpatient delivered a statistically significant benefit to ALL study patients.

February 15, 2018

·

4 min read

Drug Development

Cryoport to Provide DiscGenics With Cutting Edge Cold Chain Logistics Support for its Phase I/II Trial

Cryoport’s comprehensive, temperature-controlled logistics support services will include outbound logistics for DiscGenics’ Clinical Phase 1/2 trial of IDCT to clinics in both the United States, and eventually Japan.

February 15, 2018

·

4 min read

Biotech Bay

Inflammatix Release: New Study Published in ‘Nature Communications’ Suggests Sepsis Can Be Detected By Measuring the Immune System

Inflammatix announced findings from a new study published today in Nature Communications that suggest that diagnosing and determining who will likely develop sepsis can be improved with a data-driven approach that measures the immune system response to severe infection.

February 15, 2018

·

4 min read

Policy

Knight Therapeutics and SIFI S.p.A. Announce Filing of New Drug Submission for NETILDEX in Canada

Knight Therapeutics and SIFI S.p.A. today announced that Knight’s New Drug Submission (NDS) for NETILDEX has been accepted for review by Health Canada.

February 15, 2018

·

3 min read

Bio NC

Argos Announces Issuance of Patent Covering the Foundation for Manufacturing Its HIV Immunotherapy

The methods described in this patent form the foundation for the manufacture of AGS-004, Argos’ novel, dendritic cell-based immunotherapy for HIV.

February 15, 2018

·

5 min read

Deals

Debiopharm Continues the Fight Against Antibiotic Resistance With Investment in ABAC Therapeutics

This investment was made through the Debiopharm Innovation Fund, its strategic investment fund, and illustrates the synergy between the group companies in the fight against the worrying emergence of antibiotic resistance.

February 15, 2018

·

1 min read

Policy

Viz.ai Granted De Novo FDA Clearance for First Artificial Intelligence Triage Software

This regulatory clearance compliments Viz.ai’s recent European CE Mark for the product in January 2018.

February 15, 2018

·

3 min read